SEHK:9969Biotechs
Why InnoCare Pharma (SEHK:9969) Is Up 12.9% After Dual Breakthrough Therapy Wins in Cancer and Autoimmune Disease - And What's Next
In August 2026, InnoCare Pharma announced that its BTK inhibitor orelabrutinib, combined with BCL2 inhibitor mesutoclax, received Breakthrough Therapy Designation from China’s CDE for previously treated marginal zone lymphoma, following clinical data showing a 100% overall response rate and a favorable safety profile.
This recognition, alongside earlier positive Phase III results for TYK2 inhibitor fadeucravacitinib in moderate-to-severe plaque psoriasis, underscores InnoCare’s push to...